Oral vs. Injectable Semaglutide: Comparing Effects on Liver Inflammation and Oxidative Stress | Research

The takeaway

Both oral and injectable semaglutide improved liver inflammation and fibrosis markers in diabetic patients with fatty liver disease, with first-ever data on oxidative stress reduction.

First oxidative stress data
Both oral and injectable semaglutide reduced oxidative stress markers in fatty liver patients — previously unreported

What the researchers found

Both oral and injectable semaglutide reduced liver inflammation, fibrosis markers, and oxidative stress in T2D patients with MASLD — the first oxidative stress data for semaglutide.

Why it matters

Fatty liver disease is increasingly common and can progress to cirrhosis. Showing that both semaglutide formulations reduce oxidative stress adds a new dimension to its liver-protective effects.

The numbers in context

60 T2D + MASLD patients. 2:1 ratio injectable to oral. 6-month follow-up. Measured transient elastography (CAP), liver enzymes, cytokines, and peroxidation products.

How the study worked

Real-life, open-label, prospective study comparing standard doses of injectable vs. oral semaglutide in T2D patients with liver steatosis, measuring liver and systemic inflammation, fibrosis, and oxidative stress markers.

Who was studied

Adults with T2D and MASLD

What this study cannot tell us

Open-label design without blinding. Real-life study without randomization to formulations. Small sample size not specified in abstract.

How to read the evidence

Open-label, prospective, real-world study. Provides useful comparative data between formulations but lacks the rigor of a blinded randomized trial.

When this study was published

Published in 2025, providing the first head-to-head comparison of semaglutide formulations for liver outcomes.

The bigger picture

This study strengthens the case for semaglutide as a comprehensive metabolic therapy that addresses not just blood sugar and weight but also the liver inflammation and oxidative damage driving fatty liver disease progression.

Questions still open

Are there clinically meaningful differences between oral and injectable semaglutide for liver protection?
Does oxidative stress reduction persist with long-term semaglutide use?

Common questions

Is oral semaglutide as good as injectable for fatty liver?

This study suggests both formulations improve liver inflammation, fibrosis, and oxidative stress markers. The injectable may have a slight advantage, but oral semaglutide still provided meaningful liver benefits.

What is oxidative stress and why does it matter for liver disease?

Oxidative stress occurs when harmful reactive molecules damage cells. In fatty liver disease, oxidative stress drives progression from simple fat accumulation to inflammation, fibrosis, and eventually cirrhosis. Reducing it could slow disease progression.

Read the original research

Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.

Acta diabetologica, 62(9), 1429-1437

View on PubMed ↗Publisher’s paper ↗

Citation

Petralli, Giovanni; Zoppo, Alice Del; Rovera, Chiara; Raggi, Francesco; Salvati, Antonio; Moriconi, Diego; Distaso, Mariarosaria; Brunetto, Maurizia Rossana; Solini, Anna. (2025). Different formulations of semaglutide and oxidative stress in subjects with type 2 diabetes and MASLD: an open-label, real-life study.. Acta diabetologica, 62(9), 1429-1437. https://doi.org/10.1007/s00592-025-02466-7